Antiestrogen pharmacology and mechanism of action

Benita S Katzenellenbogen, Margaret A. Miller, Richard L. Eckert, Katsuichi Sudo

Research output: Contribution to journalArticle

Abstract

Antiestrogens are nonsteroidal compounds that are capable of antagonizing many of the actions of estrogens. They have long half-lives in serum, and during their action in vivo, the antiestrogens CI628, U23,469 and tamoxifen undergo bioactivation to more polar forms that have a higher affinity for the estrogen receptor. Utilizing the high affinity antiestrogens CI628M and trans-hydroxytamoxifen in radiolabeled form, we find differences in the interaction of the estradiol-receptor complex and antiestrogen-receptor complex with DNA cellulose and differences in their association in the nucleus. In MCF-7 human breast cancer cells, there are marked differences in the sedimentation rate and chromatographic properties of the nuclear estrogen receptor when complexed with antiestrogen (5.5 ± 0.06 s, 5.93 ± 0.20 nm Stokes radius, 137,000 mol. wt) as opposed to estrogen (4.1 ± 0.03 s, 4.84 ± 0.20 nm Stokes radius, 83,000 mol. wt). Our data are consistent with the association of the antiestrogen-receptor with an additional nuclear protein of approx. 55,000 mol. wt. This antiestrogen promoted change in receptor association with another cellular component, which may function as a possible nuclear “blocking protein” and the alterations in antiestrogen-receptor association with DNA and nuclei, may be important aspects of the estrogen antagonist and growth inhibiting properties of these compounds. In addition to binding directly to the estrogen receptor, antiestrogens can be found associated with binding sites that are distinct from the estrogen receptor. These sites are present in a wide variety of estrogen target and non-target tissues in the rat, and in estrogen receptor positive and negative human breast cancer cell lines (MCF-7, T47D, MDA-MD-231) that differ markedly in their sensitivity to antiestrogens. These sites have a subcellular distribution and ligand binding specificity very different from those of the estrogen receptor. While their wide distribution and order of binding affinities for different antiestrogens raise questions about their role in mediating directly the classically recognized estrogen antagonism of antiestrogens, these sites might alter the apparent distribution volume of antiestrogens and hence their biological potency and pharmacokinetics.

Original languageEnglish (US)
Pages (from-to)59-68
Number of pages10
JournalJournal of Steroid Biochemistry
Volume19
Issue number1
DOIs
StatePublished - Jan 1 1983

Fingerprint

Estrogen Receptor Modulators
Pharmacology
Estrogen Receptors
Estrogens
Nuclear Proteins
Nitromifene
Cells
Breast Neoplasms
Estradiol Receptors
Estrogen Antagonists
Pharmacokinetics
Tamoxifen
Sedimentation
Rats

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology

Cite this

Antiestrogen pharmacology and mechanism of action. / Katzenellenbogen, Benita S; Miller, Margaret A.; Eckert, Richard L.; Sudo, Katsuichi.

In: Journal of Steroid Biochemistry, Vol. 19, No. 1, 01.01.1983, p. 59-68.

Research output: Contribution to journalArticle

Katzenellenbogen, Benita S ; Miller, Margaret A. ; Eckert, Richard L. ; Sudo, Katsuichi. / Antiestrogen pharmacology and mechanism of action. In: Journal of Steroid Biochemistry. 1983 ; Vol. 19, No. 1. pp. 59-68.
@article{35327bd266a4457586fa78d70b319339,
title = "Antiestrogen pharmacology and mechanism of action",
abstract = "Antiestrogens are nonsteroidal compounds that are capable of antagonizing many of the actions of estrogens. They have long half-lives in serum, and during their action in vivo, the antiestrogens CI628, U23,469 and tamoxifen undergo bioactivation to more polar forms that have a higher affinity for the estrogen receptor. Utilizing the high affinity antiestrogens CI628M and trans-hydroxytamoxifen in radiolabeled form, we find differences in the interaction of the estradiol-receptor complex and antiestrogen-receptor complex with DNA cellulose and differences in their association in the nucleus. In MCF-7 human breast cancer cells, there are marked differences in the sedimentation rate and chromatographic properties of the nuclear estrogen receptor when complexed with antiestrogen (5.5 ± 0.06 s, 5.93 ± 0.20 nm Stokes radius, 137,000 mol. wt) as opposed to estrogen (4.1 ± 0.03 s, 4.84 ± 0.20 nm Stokes radius, 83,000 mol. wt). Our data are consistent with the association of the antiestrogen-receptor with an additional nuclear protein of approx. 55,000 mol. wt. This antiestrogen promoted change in receptor association with another cellular component, which may function as a possible nuclear “blocking protein” and the alterations in antiestrogen-receptor association with DNA and nuclei, may be important aspects of the estrogen antagonist and growth inhibiting properties of these compounds. In addition to binding directly to the estrogen receptor, antiestrogens can be found associated with binding sites that are distinct from the estrogen receptor. These sites are present in a wide variety of estrogen target and non-target tissues in the rat, and in estrogen receptor positive and negative human breast cancer cell lines (MCF-7, T47D, MDA-MD-231) that differ markedly in their sensitivity to antiestrogens. These sites have a subcellular distribution and ligand binding specificity very different from those of the estrogen receptor. While their wide distribution and order of binding affinities for different antiestrogens raise questions about their role in mediating directly the classically recognized estrogen antagonism of antiestrogens, these sites might alter the apparent distribution volume of antiestrogens and hence their biological potency and pharmacokinetics.",
author = "Katzenellenbogen, {Benita S} and Miller, {Margaret A.} and Eckert, {Richard L.} and Katsuichi Sudo",
year = "1983",
month = "1",
day = "1",
doi = "10.1016/S0022-4731(83)80007-7",
language = "English (US)",
volume = "19",
pages = "59--68",
journal = "Journal of Steroid Biochemistry and Molecular Biology",
issn = "0960-0760",
publisher = "Elsevier Limited",
number = "1",

}

TY - JOUR

T1 - Antiestrogen pharmacology and mechanism of action

AU - Katzenellenbogen, Benita S

AU - Miller, Margaret A.

AU - Eckert, Richard L.

AU - Sudo, Katsuichi

PY - 1983/1/1

Y1 - 1983/1/1

N2 - Antiestrogens are nonsteroidal compounds that are capable of antagonizing many of the actions of estrogens. They have long half-lives in serum, and during their action in vivo, the antiestrogens CI628, U23,469 and tamoxifen undergo bioactivation to more polar forms that have a higher affinity for the estrogen receptor. Utilizing the high affinity antiestrogens CI628M and trans-hydroxytamoxifen in radiolabeled form, we find differences in the interaction of the estradiol-receptor complex and antiestrogen-receptor complex with DNA cellulose and differences in their association in the nucleus. In MCF-7 human breast cancer cells, there are marked differences in the sedimentation rate and chromatographic properties of the nuclear estrogen receptor when complexed with antiestrogen (5.5 ± 0.06 s, 5.93 ± 0.20 nm Stokes radius, 137,000 mol. wt) as opposed to estrogen (4.1 ± 0.03 s, 4.84 ± 0.20 nm Stokes radius, 83,000 mol. wt). Our data are consistent with the association of the antiestrogen-receptor with an additional nuclear protein of approx. 55,000 mol. wt. This antiestrogen promoted change in receptor association with another cellular component, which may function as a possible nuclear “blocking protein” and the alterations in antiestrogen-receptor association with DNA and nuclei, may be important aspects of the estrogen antagonist and growth inhibiting properties of these compounds. In addition to binding directly to the estrogen receptor, antiestrogens can be found associated with binding sites that are distinct from the estrogen receptor. These sites are present in a wide variety of estrogen target and non-target tissues in the rat, and in estrogen receptor positive and negative human breast cancer cell lines (MCF-7, T47D, MDA-MD-231) that differ markedly in their sensitivity to antiestrogens. These sites have a subcellular distribution and ligand binding specificity very different from those of the estrogen receptor. While their wide distribution and order of binding affinities for different antiestrogens raise questions about their role in mediating directly the classically recognized estrogen antagonism of antiestrogens, these sites might alter the apparent distribution volume of antiestrogens and hence their biological potency and pharmacokinetics.

AB - Antiestrogens are nonsteroidal compounds that are capable of antagonizing many of the actions of estrogens. They have long half-lives in serum, and during their action in vivo, the antiestrogens CI628, U23,469 and tamoxifen undergo bioactivation to more polar forms that have a higher affinity for the estrogen receptor. Utilizing the high affinity antiestrogens CI628M and trans-hydroxytamoxifen in radiolabeled form, we find differences in the interaction of the estradiol-receptor complex and antiestrogen-receptor complex with DNA cellulose and differences in their association in the nucleus. In MCF-7 human breast cancer cells, there are marked differences in the sedimentation rate and chromatographic properties of the nuclear estrogen receptor when complexed with antiestrogen (5.5 ± 0.06 s, 5.93 ± 0.20 nm Stokes radius, 137,000 mol. wt) as opposed to estrogen (4.1 ± 0.03 s, 4.84 ± 0.20 nm Stokes radius, 83,000 mol. wt). Our data are consistent with the association of the antiestrogen-receptor with an additional nuclear protein of approx. 55,000 mol. wt. This antiestrogen promoted change in receptor association with another cellular component, which may function as a possible nuclear “blocking protein” and the alterations in antiestrogen-receptor association with DNA and nuclei, may be important aspects of the estrogen antagonist and growth inhibiting properties of these compounds. In addition to binding directly to the estrogen receptor, antiestrogens can be found associated with binding sites that are distinct from the estrogen receptor. These sites are present in a wide variety of estrogen target and non-target tissues in the rat, and in estrogen receptor positive and negative human breast cancer cell lines (MCF-7, T47D, MDA-MD-231) that differ markedly in their sensitivity to antiestrogens. These sites have a subcellular distribution and ligand binding specificity very different from those of the estrogen receptor. While their wide distribution and order of binding affinities for different antiestrogens raise questions about their role in mediating directly the classically recognized estrogen antagonism of antiestrogens, these sites might alter the apparent distribution volume of antiestrogens and hence their biological potency and pharmacokinetics.

UR - http://www.scopus.com/inward/record.url?scp=0020604564&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020604564&partnerID=8YFLogxK

U2 - 10.1016/S0022-4731(83)80007-7

DO - 10.1016/S0022-4731(83)80007-7

M3 - Article

C2 - 6887873

AN - SCOPUS:0020604564

VL - 19

SP - 59

EP - 68

JO - Journal of Steroid Biochemistry and Molecular Biology

JF - Journal of Steroid Biochemistry and Molecular Biology

SN - 0960-0760

IS - 1

ER -